Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 08 2019 - 7:00AM
Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage
immuno-oncology company developing neoantigen-based
therapeutics, today announced that Hugh O’Dowd, Chief
Executive Officer of Neon, will present at the Bank of America
Merrill Lynch 2019 Health Care Conference on Wednesday, May
15, 2019 at 5:00 p.m. PT (8:00 p.m. ET).
A live webcast of the presentation will be available by visiting
the Investors section of Neon Therapeutics’ website
at ir.neontherapeutics.com. A replay of the webcast will be
archived on the Neon Therapeutics website for 30 days
following the presentation.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology
company and a leader in the field of neoantigen-targeted therapies,
dedicated to transforming the treatment of cancer by directing the
immune system towards neoantigens. Neon is using its neoantigen
platform to develop both vaccine and T cell therapies, including
NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of
metastatic melanoma, non-small cell lung cancer, and bladder
cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment
of solid tumors; and NEO-SV-01, a neoantigen vaccine for the
treatment of a subset of hormone receptor-positive breast
cancer.
For more information, please
visit www.neontherapeutics.com.
Investor Contact:Paul Cox, Corporate Affairs
and Strategypcox@neontherapeutics.com617-337-4762
Media Contact:Stephanie Simon, Ten Bridge
Communicationsstephanie@tenbridgecommunications.com
617-581-9333
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Apr 2024 to May 2024
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Neon Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles